Gain Therapeutics’ Post

View organization page for Gain Therapeutics, graphic

4,583 followers

Thank you for the coverage Labiotech.eu and Roohi Mariam Peter. "Clinical candidate gains ground in Parkinson’s trial" American biotech Gain Therapeutics saw promising preclinical results for a Parkinson’s trial recently. Its lead candidate, which is being studied in #Alzheimer’s disease and genetic disorders like #Gaucher disease, was able to slow the progression of #Parkinson’s disease in a mouse model. The drug GT-02287 is an oral protein modulator, which restores the function of an enzyme called #GCase that becomes misfolded due to a gene mutation linked to Parkinson’s disease. By getting the enzyme to function properly, the aggregation of α-synuclein – the hallmark of Parkinson’s – reduces and so does neuroinflammation in the brain. This was reflected in a task given to these mice. The drug was tested to find out the ability of mice to build nests, a task that resembles daily living and requires cognitive thinking. Mice with Parkinson’s who were given the treatment had improved motor function and were able to build nests similar to those without Parkinson’s but nests of those who did not receive treatment were poorly built. The data was presented at the Federation of European Neuroscience Societies - FENS Forum in Austria last week. The drug is now being evaluated in a phase 1 trial and has a good safety and tolerability profile so far. https://lnkd.in/exCStWZw

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics